Who is the CEO of Bioverativ, a Sanofi company?

John Cox served as the CEO of Bioverativ, leading its spin-off from Biogen and its subsequent acquisition by Sanofi.

How many employees does Bioverativ, a Sanofi company have?

Bioverativ had nearly 500 employees at the time of its acquisition by Sanofi.

What industry is Bioverativ, a Sanofi company in?

Bioverativ, a Sanofi company operates in Biotechnology.

Is Bioverativ, a Sanofi company still active?

Yes, Bioverativ, a Sanofi company was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.

How do I sell to Bioverativ, a Sanofi company?

Research Bioverativ, a Sanofi company's priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details.

Data Surfer

How it works Insights Pricing FAQ Contact Login

Bioverativ, a Sanofi company

Biotechnology

39 employees

bioverativ.com

Verified active February 2, 2026

Key Highlights

Bioverativ is a Sanofi company focused on rare blood disorders like hemophilia.
The company is dedicated to transforming lives through world-class research and development.
It is an American multinational biotechnology company.
Bioverativ's core mission involves developing treatments for hemophilia patients.
The company targets rare blood disorders beyond hemophilia as well.

About Bioverativ, a Sanofi company

Bioverativ, a Sanofi company, is an American multinational biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research and development.

Leadership Team

John Cox

CEO

Tip: The CEO isn't always your best path in. Data Surfer finds the champions and influencers who actually drive purchasing decisions.

Company Facts

Ownership Private Company

Stock BIVV (NASDAQ)

Revenue $1.1B

Funding Acquired

Parent Company Sanofi

Why Contact Bioverativ, a Sanofi company?

Bioverativ is a biotechnology company focused on the discovery, development, and commercialization of therapies for hemophilia and other rare blood disorders.

Who Should Contact Bioverativ, a Sanofi company for Business?

Biotechnology research, development, and commercialization of rare blood disorder therapies.

Similar Companies

Companies that compete with or operate in similar markets to Bioverativ, a Sanofi company:

Baxalta
Pfizer
Novo Nordisk

More Biotechnology Companies

Spark Therapeutics, Inc.

397 employees

REGENXBIO

391 employees

Antibody Therapeutics

4 employees

Novus Biologicals, a Bio-Techne brand

View all Biotechnology companies

Frequently Asked Questions

Who is the CEO of Bioverativ, a Sanofi company?: John Cox served as the CEO of Bioverativ, leading its spin-off from Biogen and its subsequent acquisition by Sanofi.
What does Bioverativ, a Sanofi company do?: Bioverativ is a biotechnology company focused on the discovery, development, and commercialization of therapies for hemophilia and other rare blood disorders.
How many employees does Bioverativ, a Sanofi company have?: Bioverativ had nearly 500 employees at the time of its acquisition by Sanofi.
What industry is Bioverativ, a Sanofi company in?: Bioverativ, a Sanofi company operates in Biotechnology.
Is Bioverativ, a Sanofi company still active?: Yes, Bioverativ, a Sanofi company was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.
How do I sell to Bioverativ, a Sanofi company?: Research Bioverativ, a Sanofi company's priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details. Learn how Data Surfer helps.